Abstract:AIM To evaluate the levels of metabolites and cytokines in the serum of patients with severe and non-severe idiosyncratic drug-induced liver injury (DILI) and to identify biomarkers of DILI severity. METHODS Gas chromatography-mass spectrometry (GC-MS) and ultraperformance liquid chromatography-mass spectrometry (UPLC-MS) based metabolomic approaches were used to evaluate the metabolome of serum samples from 29 DILI patients of severity grade 3 (non-severe), 27 of severity grade 4 (severe), and 36 healthy control (HC). The levels of total keratin-18 (K18), fragment K18, and 27 cytokines were determined by enzyme-linked immunosorbent assay. RESULTS The alkaline phosphatase activity ( p = 0.021) and international normalized ratio (INR) ( p < 0.001) differed significantly between the severe and non-severe groups. The severe group had a higher serum fragment K18 level than the non-severe group. A multivariate analysis showed good separation between all pairs of the HC, non-severe, and severe groups. According to the orthogonal partial least-squares-discriminant analysis (OPLS-DA) model, 14 metabolites were selected by GC-MS and 17 by UPLC-MS. Among these metabolites, the levels of 16 were increased and of 15 were decreased in the severe group. A pathway analysis revealed major changes in the primary bile acid biosynthesis and alpha-linolenic acid metabolic pathways. The levels of PDGF-bb, IP-10, IL-1Rα, MIP-1β, and TNF-α differed significantly between the severe and non-severe groups, and the levels of most of the metabolites were negatively correlated with those of these cytokines. An OPLS-DA model that included the detected metabolites and cytokines revealed clear separation of the severe and non-severe groups. CONCLUSION We identified 31 metabolites and 5 cytokines related to the severity of idiosyncratic DILI. The primary bile acid biosynthesis and alpha-linolenic acid metabolism pathways were also related to the severity of DILI. A model that incorporated the metabolites and cytokines showed clear separation between patients with severe and non-severe DILI, suggesting that these biomarkers have potential as indicators of DILI severity.

Metabolomic approaches in the discovery of potential urinary biomarkers of drug-induced liver injury (DILI)

A serum metabonomics study on drug induced liver injury by UPLC coupled with Q-TOF mass spectrometry

The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment

Metabolite biomarkers of drug-induced liver injury

Metabolomic Profiling for Histologically Fibrotic Stage in Chronic Drug-Induced Liver Injury

Progress in the biomarker discovery for drug-induced liver injury]

Novel Clinical Biomarkers for Drug-Induced Liver Injury.

Alteration of Bile Acids and Omega-6 PUFAs Are Correlated With the Progression and Prognosis of Drug-Induced Liver Injury

Metabolomics and Cytokine Analysis for Identification of Severe Drug-Induced Liver Injury.

Exploring Individual Variability in Drug-Induced Liver Injury (DILI) Responses through Metabolomic Analysis

Serum Metabolome and Targeted Bile Acid Profiling Reveals Potential Novel Biomarkers for Drug-Induced Liver Injury.

Advances in drug-induced liver injury research: in vitro models, mechanisms, omics and gene modulation techniques

Salivary metabolites are promising noninvasive biomarkers of drug-induced liver injury

MicroRNAs in Drug-induced Liver Injury.

Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans

Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: An international collaborative effort

Metabolomics analysis for biomarker discovery: advances and challenges

The Immunological Mechanisms and Immune-Based Biomarkers of Drug-Induced Liver Injury

Dissecting the molecular pathophysiology of drug-induced liver injury

An ensemble learning approach for modeling the systems biology of drug-induced injury

Development of novel tools for the in vitro investigation of drug-induced liver injury